Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Interventions for cutaneous disease in systemic lupus erythematosus.
Cochrane Database Syst Rev
March 2021
Office of Research and Innovation, Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn, Dublin, Ireland.
Background: Lupus erythematosus is an autoimmune disease with significant morbidity and mortality. Cutaneous disease in systemic lupus erythematosus (SLE) is common. Many interventions are used to treat SLE with varying efficacy, risks, and benefits.
View Article and Find Full Text PDFEndemic carbapenem-nonsusceptible complex in intensive care units of the national referral hospital in Jakarta, Indonesia.
Antimicrob Resist Infect Control
June 2019
2Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Background: Carbapenem-nonsusceptible complex have emerged worldwide, but the epidemiology in Indonesian hospitals has not been studied.
Methods: A prospective observational study was performed on the intensive care units (ICUs) of the national referral hospital in Jakarta-Indonesia, in 2013 and 2014. All consecutive adult patients admitted and hospitalized for >48 h in ICUs were included.
Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks?
J Pharm Pharm Sci
November 2017
Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi, USA.
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique, non-β-lactam β-lactamase inhibitor. This review conducts a thorough examination of structure, pharmacology, spectrum of activity, pharmacokinetics/pharmacodynamics, in vitro and clinical efficacy and safety/tolerability of ceftazidime/avibactam, as well as detailed future directions for the agent.
View Article and Find Full Text PDFLow bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.
Cochrane Database Syst Rev
April 2016
Department of Paediatric Oncology, Emma Children's Hospital/Academic Medical Center, PO Box 22660 (room H4-139), Amsterdam, Netherlands, 1100 DD.
Article Synopsis
- Neutropenia, a side effect of chemotherapy that increases infection risk, has led to the exploration of low bacterial diets (LBD) as a preventive measure against infection and related mortality in cancer patients.
- The main aim of this review is to evaluate how effective LBDs are compared to control diets in preventing infections and reducing death rates due to infections in both adult and pediatric cancer patients undergoing chemotherapy.
- The review includes a comprehensive search of multiple medical databases and conference proceedings to gather relevant studies and information on this topic.
Purpose: Multidrug-resistant gram-negative bacterial infections have emerged as a major threat in hospitalized patients. Treatment options are often inadequate and, as a result, these infections are associated with high mortality. A cephalosporin and a novel synthetic non-β-lactam, β-lactamase inhibitor, ceftazidime-avibactam, is approved for the treatment of serious infections caused by resistant gram-negative bacteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!